Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Updates (for clubhouse)

<< Previous

Bullboard Posts

Next >>

Comment by Pragmatiston Feb 27, 2021 1:03am

198 Views

Post# 32678003

RE:RE:RE:RE:RE:RE:Updates (for clubhouse)

I did that. The ads remained. Duster disappeared!

Just joking! I appreciate his postings. His calls are generally good. Maybe his presentation needs some work.

One should take all postings on this board with a grain of salt. If they are backed up with some facts, then maybe they are something that you should consider. And if not, well..they are just opinions. Just look at everything with a critical eye.

I have followed your prior posts on this board, Pandora, so I am interested in what you have to say.

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program